PHARMACIES: Provides relative to pharmaceutical costs (OR +$153,127 GF EX See Note)

HB 918 requires Louisiana's Department of Health to create a list of "critical prescription drugs" based on factors like cost to Medicaid, usage, and availability of alternatives. Drug manufacturers must report detailed cost data (including production, R&D, marketing, and international pricing) for drugs on this list. The bill also mandates that marketing materials to healthcare providers include current wholesale prices for each drug. These transparency measures aim to inform pricing decisions without directly setting drug costs.